MedTrace Logo

ET-01 in Subjects With Lateral Canthal Lines, LCL-207

NCT03655691 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2022-04-21

Study results available
· View outcomes & findings →

Summary

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Conditions

  • Lateral Canthal Lines
  • Crow's Feet

Interventions

BIOLOGICAL

Vehicle

Vehicle Formulation

BIOLOGICAL

botulinum toxin, Type A

botulinum toxin, Type A, lower Dose 1, administered once, topically, at Baseline

BIOLOGICAL

botulinum toxin, Type A

botulinum toxin, Type A, higher Dose 2, administered once, topically, at Baseline

Sponsors & Collaborators

  • Eirion Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Klaus Theobald, MD, PhD · Eirion Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-16
Primary Completion
2018-11-09
Completion
2019-04-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03655691 on ClinicalTrials.gov